NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety,Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants withPreviously Treated Hematologic Malignancies

The purpose of this study is to determine the safety at different dose levels, tolerance, and possible side effects of LY4584180, alone and in combination with another anticancer therapy (drug named rituximab), in participants with lymphoma. LY4584180 has not been approved by the Food and Drug Administration (FDA).

Are you Eligible? (Inclusion Criteria)

• Must be 18 years old or older - Cannot be part of another study at the same time - Must have life expectancy greater than 2 years